Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Karolin Isaksson"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł :
CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients
Autorzy :
Siker Kimbung
Maria Inasu
Tor Stålhammar
Björn Nodin
Karin Elebro
Helga Tryggvadottir
Maria Ygland Rödström
Karin Jirström
Karolin Isaksson
Helena Jernström
Signe Borgquist
Pokaż więcej
Temat :
Cholesterol
27-hydroxycholesterol
CYP27A1
Breast cancer
Prognosis
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Breast Cancer Research , Vol 22, Iss 1, Pp 1-13 (2020)
Opis pliku :
electronic resource
Relacje :
http://link.springer.com/article/10.1186/s13058-020-01347-x; https://doaj.org/toc/1465-542X
Dostęp URL :
https://doaj.org/article/dc9b2df2276b447bbb83d11c19cb5da6
Czasopismo naukowe
Tytuł :
Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer—Impact on Prognosis
Autorzy :
Linn Nilsson
Emma Sandén
Somayeh Khazaei
Helga Tryggvadottir
Björn Nodin
Karin Jirström
Signe Borgquist
Karolin Isaksson
Helena Jernström
Pokaż więcej
Temat :
signal transducer and activator of transcription 3 (STAT3)
breast cancer
prognosis
immunohistochemistry
tamoxifen
lifestyle
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Frontiers in Oncology, Vol 10 (2020)
Opis pliku :
electronic resource
Relacje :
https://www.frontiersin.org/article/10.3389/fonc.2020.01278/full; https://doaj.org/toc/2234-943X
Dostęp URL :
https://doaj.org/article/c7b4e999371b47f68a63299f71ad4c32
Czasopismo naukowe
Tytuł :
Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment
Autorzy :
Christopher Godina
Erik Ottander
Helga Tryggvadottir
Signe Borgquist
Karolin Isaksson
Helena Jernström
Pokaż więcej
Temat :
breast cancer
menopausal hormone therapy
prognosis
aromatase inhibitor
cohort
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Frontiers in Oncology, Vol 10 (2020)
Opis pliku :
electronic resource
Relacje :
https://www.frontiersin.org/article/10.3389/fonc.2020.00080/full; https://doaj.org/toc/2234-943X
Dostęp URL :
https://doaj.org/article/378227b51b54441f937e5d29ba8d8cf2
Czasopismo naukowe
Tytuł :
Participation in a Prospective Cohort Study on Melanoma did not Affect the Incidence and Mortality of the Studied Disease
Autorzy :
Åsa M. Ingvar
Håkan Olsson
Per Broberg
Karolin Isaksson
Christian Ingvar
Kari Nielsen
Pokaż więcej
Temat :
malignant melanoma
incidence
mortality
cohort study
Dermatology
RL1-803
Źródło :
Acta Dermato-Venereologica, Vol 100, Iss 1, p adv00010 (2020)
Opis pliku :
electronic resource
Relacje :
https://www.medicaljournals.se/jadv/content/html/10.2340/00015555-3362; https://doaj.org/toc/0001-5555; https://doaj.org/toc/1651-2057
Dostęp URL :
https://doaj.org/article/6d460f820bc34d1fbde8050954b44b6f
Czasopismo naukowe
Tytuł :
Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
Autorzy :
Olofsson Bagge R; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Kicinski M; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Faries MB; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Gyorki DE; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Isaksson K; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Katsarelias D; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Lo S; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Moncrieff M; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Spillane A; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Suciu S; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
van Akkooi A; R. Olofsson Bagge, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Michal Kicinski, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Mark B. Faries, MD, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA; David E. Gyorki, MD, FRACS, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Karolin Isaksson, MD, PhD, Department of Clinical Sciences Lund, Surgery, Lund University, Lund; and Department of Surgery, Central Hospital Kristianstad, Kristianstad, Sweden; Dimitrios Katsarelias, MD, PhD, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital; and Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Serigne Lo, PhD, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Marc Moncrieff, MD, FRCS(Plast), Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; Andrew Spillane, MD, FRACS, Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Stefan Suciu, MSc, PhD, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; and Alexander van Akkooi, MD, PhD, Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Sep 20; Vol. 38 (27), pp. 3233-3234. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :
Letter
Opinia redakcyjna
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies